Broker Recommendations
HSBC trims Lloyds target price and upgrades RBS, but prefers Barclays
Analysts at HSBC sounded a more positive note on RBS and Barclays on Friday, but not Lloyds, following the 15-20% decline in their share prices over the past three months, on the back of concerns around geopolitics (and Brexit).
'Last bear in town' Liberum ups Glencore to 'hold'
"Last bear in town" Liberum upped its stance on Glencore to 'hold' from 'sell' on Friday, meaning there are no more 'sell' ratings around on the miner.
BofA-ML retains bearish stance ahead of 10-year commemoration of Lehman Bros. crash
Investors are already positioned 'bearishly', but that potential positive for financial markets was likely to be swamped by the recent peaks in corporate profits and economic stimulus, strategists at Bank of America-Merrill Lynch cautioned.
KAZ Minerals sinks as analysts fret about Baimskaya risks
KAZ Minerals was downgraded to 'neutral' by analysts at Credit Suisse on Friday, while UBS slashed its share price target.
Buy platinum metal rather than the miners, says ShoreCap
Prospects of industrial action in South Africa could make speculation in platinum worthwhile, suggested stockbroker Shore Capital on Friday.
Berenberg ups target price on Huntsworth after 'better than expected' first half
Analysts at Berenberg updated their forecasts on Huntsworth following the healthcare and communications group's "better than expected" first half.
UBS upgrades Esure to 'neutral' after Bain deal
UBS upgraded Esure to 'neutral' from 'sell' and hiked the price target to 280p after the insurer agreed to be bought by private equity firm Bain Capital for 280p a share, as it said there is a high probability of deal success.
Morgan Stanley downgrades Informa but still sees attractions
Morgan Stanley downgraded Informa after its results did not impress last month, though there was still lots to like about the exhibitions organiser and business publisher.
Peel Hunt upgrades Hikma, says upgrade cycle will drive shares
Peel Hunt upgraded Hikma Pharmaceuticals to 'add' from 'hold' on Thursday and bumped up the price target to 1,950p from 1,160p following the company's "strong" first-half results a day earlier.
IQE one of 'best placed' superconductor supply chain - Barclays
Barclays analysts consider IQE one of the "best placed names" in the superconductor supply chain, but trimmed its target price on the Cardiff based company on Wednesday.
Barclays reiterates 'overweight' on Chemring, spies entrypoint into shares
Analysts at Barclays Research reiterated their 'overweight' stance on stock of Chemring following the tragic incident at the firm's countermeasures facility near Salisbury on 13 August.
Peel Hunt reiterates 'buy' rating on 'well positioned' TBC Bank
Analysts at Peel Hunt reiterated their 'buy' rating on TBC Bank on Wednesday, saying they were "confident" the Georgian banking group's underlying results would again highlight the consistency of its returns.
Berenberg upgrades Esure, says Bain deal is 'excellent outcome' for shareholders
Berenberg upgraded Esure to 'hold' from 'sell' and lifted the price target to 280p from 230p after the insurer agreed to be bought by Bain Capital for 280p a share in cash.
Card Factory downgraded at Berenberg following profit warning
Analysts at Berenberg downgraded Card Factory to 'sell' on Tuesday, noting that the firm's "weak" first half trading update made it look like the retailer was "struggling to find momentum".
Elementis rallies on Berenberg upgrade to 'buy'
Elementis shares rose on Tuesday as Berenberg upgraded the speciality chemicals and personal care business to 'buy' from 'hold', saying it's undervalued and the market is assuming the worst as far as its acquisition of Mondo Minerals is concerned.
Likelihood of capital controls in Turkey rising, Jefferies says
The likelihood that Turkey will impose some degree of capital controls is rising with each passing minute, given President Recep Tayyip Erdogan's refusal to allow the central bank to hike interest rates, analysts at Jefferies said.
Twitter boosted after Citron sets $52 target price
Twitter’s shares were given a boost on Monday after online investment newsletter Citron Research predicted that the social media giant’s shares will hit $52 within a year.